Drugs / INFRADURE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01433133 | Oct 2012 → Oct 2013 | hepatitis C virus infection | Medgenics Medical Israel Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INFRADURE | “Medgenics Inc. and Medgenics Medical Israel Ltd. are developing INFRADURE, an autologous dermal biopump capable of sustained secretion of therapeutic INF in the body” NCT01433133 ↗ |
| Route | Subcutaneous | “The INFRADURE Biopump is subsequently implanted subcutaneously back to the patient” NCT01433133 ↗ |